Penumbra to launch Lantern microcatheter and present final results of multicentre PRISM trial


Penumbra has announced the launch of its Lantern microcatheter at the upcoming Society for Interventional Radiology 2016 meeting (SIR 2016; 2–7 April, Vancouver, Canada).

Lantern is a low profile, high flow microcatheter designed to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic devices, such as occlusion coils, to the peripheral vasculature. Lantern adds to Penumbra’s growing embolisation portfolio and aids the delivery of embolisation devices including RUBY Coil, POD (Penumbra Occlusion Device) and POD Packing Coil. In addition, the final results of the multicentre PRISM study, designed to assess the safety and efficacy of the Indigo system for peripheral and visceral arterial thrombi and emboli, will be presented. The Indigo System is a novel mechanical aspiration system for the removal of emboli and thrombi in the peripheral vasculature.

Lantern received 510(k) clearance from the US Food and Drug Administration (FDA) in December 2015. It is offered in a variety of lengths and tip shapes relevant to peripheral vascular procedures. Lantern’s distal segment is visible under fluoroscopy to aid in the navigation and visualisation of the microcatheter during procedures.

“Like many Penumbra products, the Lantern microcatheter is unique in its design and helps address physician needs for a low profile, high flow microcatheter,” said Adam Elsesser, chairman and chief executive officer of Penumbra. “It is designed to track distally through the peripheral vasculature, yet can be used for high flow contrast injections, combining these desired properties into one microcatheter.”